Dear AuntMinnieEurope member,
Theranostics is on the rise in Europe, but patient access to radiopharmaceuticals varies considerably between countries. Our featured article this week explores this challenge and the need for regulatory systems to evolve alongside scientific advances.
The clinical application of PET RANO 1.0 – the first international criteria for standardized amino acid PET response assessment in diffuse gliomas – is also an important development. Click here for our report.
It can be hard to admit mistakes, but sharing these experiences can be a great way for radiologists to learn and contribute to improved patient care, according to a new column from Dr. Giles Maskell of Royal Cornwall Hospitals National Health Service (NHS) Trust in the U.K.
A recent study found that high-resolution specimen PET/CT can improve margin assessment in breast tumors. And single-fraction stereotactic body radiotherapy is safe and effective for controlling disease in men with localized prostate cancer, according to researchers from Switzerland.
Please see below for our other top stories of the week.
Erik L. Ridley
Editor in Chief
AuntMinnieEurope.com
1. As theranostics advances, access challenges remain across Europe
2. PET RANO gains visibility as neurotheranostics research advances
3. Six European societies launch RLT Referral Pathways Project
4. One conference, three lessons
5. PET/CT could improve margin assessment for breast tumors
6. Single-fraction SBRT a valid option for localized prostate cancer
7. Novel SST2-PET tracer shows promise in patients with NETs
8. $9M grant invests in ‘next generation’ of CAA scientists
9. BrightHeart receives CE mark for prenatal ultrasound AI platform
10. Sectra signs enterprise imaging deal with German radiology group